STAT+: Europe will accelerate its review of RevMed’s drug

Europe's decision to speed up its review of RevMed’s drug highlights growing concerns about Kailera's GLP-1 pill, which is under scrutiny for potential issues. This move underscores the heightened scrutiny in the pharmaceutical industry as regulators demand more rigorous data to ensure safety and efficacy. With the FDA also clearing a new autoimmune therapy, the biotech sector is abuzz with significant regulatory developments that could impact treatment options and investor confidence. These actions reflect a broader trend towards more stringent oversight in drug approval processes.